CA2648578A1 - Formulations de polysulfate de pentosane stabilise (pps) et procedes d'analyse de ces dernieres - Google Patents

Formulations de polysulfate de pentosane stabilise (pps) et procedes d'analyse de ces dernieres Download PDF

Info

Publication number: CA2648578A1
Authority: CA; Canada
Prior art keywords: formulation; pps; concentration; dosage form; bell
Prior art date: 2006-04-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002648578A

Other languages

English (en)

Inventor

Jerry A. Ellinghuysen

Charles Filburn

David Griffin

Todd R. Henderson

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Nutramax Laboratories Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-04-03

Filing date

2007-04-03

Publication date

2007-11-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38625506&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2648578(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-04-03 Application filed by Individual filed Critical Individual

2007-11-01 Publication of CA2648578A1 publication Critical patent/CA2648578A1/fr

Status Abandoned legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 275
238000009472 formulation Methods 0.000 title claims abstract description 259
229940043138 pentosan polysulfate Drugs 0.000 title claims abstract description 223
238000000034 method Methods 0.000 title claims description 61
238000005251 capillar electrophoresis Methods 0.000 claims abstract description 56
241000124008 Mammalia Species 0.000 claims abstract description 35
230000001954 sterilising effect Effects 0.000 claims abstract description 32
238000004659 sterilization and disinfection Methods 0.000 claims abstract description 29
238000004458 analytical method Methods 0.000 claims abstract description 24
208000005615 Interstitial Cystitis Diseases 0.000 claims abstract description 7
201000008482 osteoarthritis Diseases 0.000 claims abstract description 7
238000001962 electrophoresis Methods 0.000 claims description 99
239000002552 dosage form Substances 0.000 claims description 51
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 48
239000000872 buffer Substances 0.000 claims description 36
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 27
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 25
239000007857 degradation product Substances 0.000 claims description 25
229920001542 oligosaccharide Polymers 0.000 claims description 25
150000002482 oligosaccharides Chemical class 0.000 claims description 25
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 22
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 20
235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 20
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 19
238000005057 refrigeration Methods 0.000 claims description 19
238000010521 absorption reaction Methods 0.000 claims description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
239000012669 liquid formulation Substances 0.000 claims description 17
150000002337 glycosamines Chemical class 0.000 claims description 12
238000002347 injection Methods 0.000 claims description 12
239000007924 injection Substances 0.000 claims description 12
239000007788 liquid Substances 0.000 claims description 12
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 12
239000000243 solution Substances 0.000 claims description 12
239000004599 antimicrobial Substances 0.000 claims description 11
239000003963 antioxidant agent Substances 0.000 claims description 11
239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 11
229960002216 methylparaben Drugs 0.000 claims description 11
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 10
239000001509 sodium citrate Substances 0.000 claims description 10
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 10
230000003442 weekly effect Effects 0.000 claims description 10
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 9
239000002738 chelating agent Substances 0.000 claims description 9
229920002674 hyaluronan Polymers 0.000 claims description 9
229960003160 hyaluronic acid Drugs 0.000 claims description 9
208000024777 Prion disease Diseases 0.000 claims description 8
208000010544 human prion disease Diseases 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 8
208000007536 Thrombosis Diseases 0.000 claims description 7
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 7
230000010354 integration Effects 0.000 claims description 7
JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 claims description 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
229910019142 PO4 Inorganic materials 0.000 claims description 6
201000010099 disease Diseases 0.000 claims description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 6
239000010452 phosphate Substances 0.000 claims description 6
201000001320 Atherosclerosis Diseases 0.000 claims description 5
208000001034 Frostbite Diseases 0.000 claims description 5
WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 claims description 5
208000014617 hemorrhoid Diseases 0.000 claims description 5
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 4
208000030507 AIDS Diseases 0.000 claims description 4
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
206010061598 Immunodeficiency Diseases 0.000 claims description 4
208000029462 Immunodeficiency disease Diseases 0.000 claims description 4
241000700605 Viruses Species 0.000 claims description 4
229960002442 glucosamine Drugs 0.000 claims description 4
230000007813 immunodeficiency Effects 0.000 claims description 4
CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical group Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 claims description 3
MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 claims description 3
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 claims description 3
MSWZFWKMSRAUBD-CBPJZXOFSA-N 2-amino-2-deoxy-D-mannopyranose Chemical compound N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-CBPJZXOFSA-N 0.000 claims description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 3
239000004471 Glycine Substances 0.000 claims description 3
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 3
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 3
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 3
229960001911 glucosamine hydrochloride Drugs 0.000 claims description 3
229960002849 glucosamine sulfate Drugs 0.000 claims description 3
229940040102 levulinic acid Drugs 0.000 claims description 3
229950006780 n-acetylglucosamine Drugs 0.000 claims description 3
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 3
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
230000003078 antioxidant effect Effects 0.000 claims 6
235000006708 antioxidants Nutrition 0.000 claims 6
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 4
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims 4
239000011668 ascorbic acid Substances 0.000 claims 2
239000004405 propyl p-hydroxybenzoate Substances 0.000 claims 2
229960003415 propylparaben Drugs 0.000 claims 2
235000010378 sodium ascorbate Nutrition 0.000 claims 2
229960005055 sodium ascorbate Drugs 0.000 claims 2
230000015556 catabolic process Effects 0.000 abstract description 33
238000006731 degradation reaction Methods 0.000 abstract description 33
238000002845 discoloration Methods 0.000 abstract description 13
238000012494 forced degradation Methods 0.000 description 22
ARCGXLSVLAOJQL-UHFFFAOYSA-N trimellitic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C(C(O)=O)=C1 ARCGXLSVLAOJQL-UHFFFAOYSA-N 0.000 description 22
239000000126 substance Substances 0.000 description 21
VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 14
238000005259 measurement Methods 0.000 description 13
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 11
238000005515 capillary zone electrophoresis Methods 0.000 description 10
230000005012 migration Effects 0.000 description 10
238000013508 migration Methods 0.000 description 10
238000001514 detection method Methods 0.000 description 9
238000003908 quality control method Methods 0.000 description 8
241000283073 Equus caballus Species 0.000 description 7
238000005370 electroosmosis Methods 0.000 description 7
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 6
239000008186 active pharmaceutical agent Substances 0.000 description 6
239000000047 product Substances 0.000 description 6
238000000926 separation method Methods 0.000 description 6
239000011734 sodium Substances 0.000 description 6
229910052708 sodium Inorganic materials 0.000 description 6
238000003860 storage Methods 0.000 description 6
238000012360 testing method Methods 0.000 description 6
150000001450 anions Chemical class 0.000 description 5
238000009826 distribution Methods 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
230000031700 light absorption Effects 0.000 description 5
-1 neutral Chemical group 0.000 description 5
239000003755 preservative agent Substances 0.000 description 5
230000008569 process Effects 0.000 description 5
241000282412 Homo Species 0.000 description 4
241000725303 Human immunodeficiency virus Species 0.000 description 4
239000002253 acid Substances 0.000 description 4
239000003146 anticoagulant agent Substances 0.000 description 4
229940127219 anticoagulant drug Drugs 0.000 description 4
230000008859 change Effects 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000012634 fragment Substances 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
238000011002 quantification Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
241000713800 Feline immunodeficiency virus Species 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
239000004280 Sodium formate Substances 0.000 description 3
208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 3
125000000129 anionic group Chemical group 0.000 description 3
206010003246 arthritis Diseases 0.000 description 3
208000005881 bovine spongiform encephalopathy Diseases 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
239000003086 colorant Substances 0.000 description 3
238000000354 decomposition reaction Methods 0.000 description 3
239000012535 impurity Substances 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
244000005700 microbiome Species 0.000 description 3
HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 3
235000019254 sodium formate Nutrition 0.000 description 3
239000010902 straw Substances 0.000 description 3
230000019635 sulfation Effects 0.000 description 3
238000005670 sulfation reaction Methods 0.000 description 3
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
241000282465 Canis Species 0.000 description 2
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
241000282324 Felis Species 0.000 description 2
241000282414 Homo sapiens Species 0.000 description 2
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
JCSJTDYCNQHPRJ-MMDFAQQLSA-N beta-D-Xylp-(1->4)-beta-D-Xylp-(1->4)-beta-D-Xylp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)OC2)O)OC1 JCSJTDYCNQHPRJ-MMDFAQQLSA-N 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
239000008367 deionised water Substances 0.000 description 2
229910021641 deionized water Inorganic materials 0.000 description 2
229910052805 deuterium Inorganic materials 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
229940126534 drug product Drugs 0.000 description 2
229940088679 drug related substance Drugs 0.000 description 2
239000005350 fused silica glass Substances 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
239000002502 liposome Substances 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
229960003820 pentosan polysulfate sodium Drugs 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
238000012503 pharmacopoeial method Methods 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
150000004804 polysaccharides Chemical class 0.000 description 2
239000002994 raw material Substances 0.000 description 2
239000012146 running buffer Substances 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
229940001584 sodium metabisulfite Drugs 0.000 description 2
235000010262 sodium metabisulphite Nutrition 0.000 description 2
BAZAXWOYCMUHIX-UHFFFAOYSA-M sodium perchlorate Chemical compound [Na+].[O-]Cl(=O)(=O)=O BAZAXWOYCMUHIX-UHFFFAOYSA-M 0.000 description 2
229910001488 sodium perchlorate Inorganic materials 0.000 description 2
QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 2
239000007787 solid Substances 0.000 description 2
241000894007 species Species 0.000 description 2
238000009662 stress testing Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
241000283690 Bos taurus Species 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Natural products CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
241000009328 Perro Species 0.000 description 1
239000004642 Polyimide Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229920001586 anionic polysaccharide Polymers 0.000 description 1
150000004836 anionic polysaccharides Chemical class 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
SRBFZHDQGSBBOR-KKQCNMDGSA-N beta-D-xylose Chemical group O[C@@H]1CO[C@@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-KKQCNMDGSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000004202 carbamide Chemical class 0.000 description 1
230000006652 catabolic pathway Effects 0.000 description 1
239000003093 cationic surfactant Chemical class 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
239000001913 cellulose Chemical class 0.000 description 1
229920002678 cellulose Chemical class 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
229940068682 chewable tablet Drugs 0.000 description 1
210000001520 comb Anatomy 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
239000012809 cooling fluid Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000010586 diagram Methods 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
230000005684 electric field Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
238000012495 forced degradation study Methods 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
229950006191 gluconic acid Drugs 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
229920005555 halobutyl Polymers 0.000 description 1
125000004968 halobutyl group Chemical group 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
230000001788 irregular Effects 0.000 description 1
238000011068 loading method Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
229920000620 organic polymer Polymers 0.000 description 1
239000003960 organic solvent Chemical class 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
229940023488 pill Drugs 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001721 polyimide Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
238000000275 quality assurance Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000013589 supplement Substances 0.000 description 1
210000001179 synovial fluid Anatomy 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
210000004127 vitreous body Anatomy 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
229920001221 xylan Polymers 0.000 description 1
150000004823 xylans Chemical class 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Virology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Diabetes (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CA002648578A 2006-04-03 2007-04-03 Formulations de polysulfate de pentosane stabilise (pps) et procedes d'analyse de ces dernieres Abandoned CA2648578A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US78805206P	2006-04-03	2006-04-03
US60/788,052		2006-04-03
PCT/US2007/008066 WO2007123800A2 (fr)	2006-04-03	2007-04-03	Formulations de polysulfate de pentosane stabilisé (pps) et procédés d'analyse de ces dernières

Publications (1)

Publication Number	Publication Date
CA2648578A1 true CA2648578A1 (fr)	2007-11-01

Family

ID=38625506

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002648578A Abandoned CA2648578A1 (fr)	2006-04-03	2007-04-03	Formulations de polysulfate de pentosane stabilise (pps) et procedes d'analyse de ces dernieres

Country Status (12)

Country	Link
US (2)	US20070243218A1 (fr)
EP (1)	EP2010220B1 (fr)
JP (1)	JP5433881B2 (fr)
AU (1)	AU2007240993B2 (fr)
CA (1)	CA2648578A1 (fr)
DK (1)	DK2010220T3 (fr)
ES (1)	ES2913483T3 (fr)
HU (1)	HUE058709T2 (fr)
NZ (1)	NZ571537A (fr)
PL (1)	PL2010220T4 (fr)
PT (1)	PT2010220T (fr)
WO (1)	WO2007123800A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20090175810A1 (en)	2008-01-03	2009-07-09	Gareth Winckle	Compositions and methods for treating diseases of the nail
AU2013202633B2 (en) *	2008-07-04	2015-10-22	Parnell Technologies Pty Ltd	A sulfated polysaccharide compound and the preparation and use thereof
AU2008100730B4 (en)	2008-07-04	2008-10-02	Parnell Technologies Pty Ltd	Sulfated polysaccharide compound for clinical use and the preparation thereof
EP2437781B1 (fr) *	2009-06-04	2013-07-24	Alk AG	Composition stabilisée comprenant au moins un composé adrénergique
WO2011088418A2 (fr) *	2010-01-15	2011-07-21	Mount Sinai School Of Medicine	Inhibition par le polysulfate de pentosane de l'activation de nfkb induite par le tnf-alpha
US8039494B1 (en)	2010-07-08	2011-10-18	Dow Pharmaceutical Sciences, Inc.	Compositions and methods for treating diseases of the nail
US8716204B2 (en)	2010-07-27	2014-05-06	Zimmer, Inc.	Synthetic synovial fluid compositions and methods for making the same
WO2012027797A1 (fr) *	2010-09-02	2012-03-08	David Charles James	Composition anti-inflammatoire
WO2013054866A1 (fr) *	2011-10-13	2013-04-18	国立大学法人長崎大学	Agent pour la prévention ou le traitement d'une myélopathie associée à htlv-i
JP6228137B2 (ja) *	2012-01-30	2017-11-08	バクスアルタゲーエムベーハー	非抗凝固性の硫酸化またはスルホン酸化多糖
FR2993182B1 (fr) *	2012-07-13	2014-10-17	Urgo Lab	Pansement a liberation prolongee d'actifs
AU2014218512B2 (en) *	2013-02-20	2017-09-28	The University Of Queensland	Conjugate compound and uses of same
WO2015051183A1 (fr)	2013-10-03	2015-04-09	Dow Pharmaceutical Sciences, Inc.	Compositions d'éfinaconazole stabilisée
US10245257B2 (en)	2013-11-22	2019-04-02	Dow Pharmaceutical Sciences, Inc.	Anti-infective methods, compositions, and devices
WO2016170158A1 (fr) *	2015-04-24	2016-10-27	Bene Pharmachem Gmbh & Co. Kg	Procédé de détection et/ou de quantification de pentosane polysulfate de sodium
US20180318336A1 (en) *	2015-05-27	2018-11-08	Vanguard Therapeutics, Inc.	Pentosan polysulfate sodium for the treatment of sickle cell disease
JP6225321B1 (ja)	2016-08-31	2017-11-08	王子ホールディングス株式会社	ポリ硫酸ペントサンの製造方法
MX2020002288A (es)	2016-08-31	2020-07-14	Oji Holdings Corp	Metodo de produccion para xilooligosacarido acido y xilooligosacarido acido.
GB201616838D0 (en) *	2016-10-04	2016-11-16	Nat Univ Ireland	Hyaluronan compositions, and uses thereof in treatment of interstitial cystitis
JP6281659B1 (ja)	2017-02-28	2018-02-21	王子ホールディングス株式会社	ポリ硫酸ペントサン、医薬組成物及び抗凝固剤
WO2018213629A1 (fr) *	2017-05-18	2018-11-22	Adamis Pharmaceuticals Corporation	Compositions de médicaments
KR20240023711A (ko)	2017-05-31	2024-02-22	오지 홀딩스 가부시키가이샤	보습 외용제
MX2020002726A (es)	2017-09-12	2020-07-20	Oji Holdings Corp	Polisulfato de pentosan y metodo para producir polisulfato de pentosan.
HUE062342T2 (hu)	2017-12-20	2023-10-28	Oji Holdings Corp	Pentozán-poliszulfát, valamint pentozán-poliszulfátot tartalmazó gyógyszerek
WO2019151287A1 (fr) *	2018-01-31	2019-08-08	マルホ株式会社	Composition externe pour la peau
EP3586851A1 (fr) *	2018-06-27	2020-01-01	Nextraresearch S.r.l.	Compositions pour l'administration orale de polysulfate de pentosane et chitosan sous forme de nanoparticules à absorption intestinale améliorée
EP3842048A4 (fr) *	2018-08-20	2022-03-30	ReqMed Company, Ltd.	Nouvelle préparation de pentosane polysulfate sodique
WO2021050320A1 (fr) *	2019-09-09	2021-03-18	Harrow Ip, Llc	Compositions pharmaceutiques comprenant des héparinoïdes et leurs procédés de préparation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5668116A (en) *	1987-03-19	1997-09-16	Anthropharm Pty. Limited	Anti-inflammatory compounds and compositions
EP0356435B1 (fr) *	1987-03-19	1995-10-18	Arthropharm Pty. Limited	Composes et compositions anti-inflammatoires
US4877791A (en) *	1988-11-01	1989-10-31	Baker Cummins Pharmaceuticals, Inc.	Method of treatment for interestitial cystitis
US5643892A (en) *	1995-06-07	1997-07-01	Baker Norton Pharmaceuticals, Inc.	Method of treating chronic progressive vascular diseases
US6255295B1 (en)	1996-12-23	2001-07-03	Nutramax Laboratories, Inc.	Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue
AU2001230994A1 (en)	2000-01-19	2001-07-31	The United States of America, represented by The Secretary, Department of Health & Human Services	Use of pentosan polysulfate to treat certain conditions of the prostate
US6607745B2 (en) *	2001-05-18	2003-08-19	Harry Leneau	Ingestion of hyaluronic acid for improved joint function and health
EP2368554B1 (fr) *	2003-04-08	2014-12-24	Progenics Pharmaceuticals, Inc.	Formulations pharmaceutiques contenant de la methylnaltrexone
AU2004281520B2 (en) *	2003-10-08	2009-01-08	Novartis Ag	Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
NZ548225A (en) *	2003-12-31	2012-12-21	Cydex Pharmaceuticals Inc	Inhalant formulation containing sulfoakyl ether cyclodextrin and corticosteroid
US20050282893A1 (en)	2004-01-30	2005-12-22	Au Jessie L	Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors

2007
- 2007-04-03 NZ NZ571537A patent/NZ571537A/en unknown
- 2007-04-03 PT PT77545713T patent/PT2010220T/pt unknown
- 2007-04-03 EP EP07754571.3A patent/EP2010220B1/fr active Active
- 2007-04-03 PL PL07754571.3T patent/PL2010220T4/pl unknown
- 2007-04-03 JP JP2009504229A patent/JP5433881B2/ja active Active
- 2007-04-03 ES ES07754571T patent/ES2913483T3/es active Active
- 2007-04-03 HU HUE07754571A patent/HUE058709T2/hu unknown
- 2007-04-03 AU AU2007240993A patent/AU2007240993B2/en active Active
- 2007-04-03 US US11/730,742 patent/US20070243218A1/en not_active Abandoned
- 2007-04-03 CA CA002648578A patent/CA2648578A1/fr not_active Abandoned
- 2007-04-03 WO PCT/US2007/008066 patent/WO2007123800A2/fr active Application Filing
- 2007-04-03 DK DK07754571.3T patent/DK2010220T3/da active
2011
- 2011-02-28 US US13/036,995 patent/US20110212914A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ES2913483T3 (es)	2022-06-02
DK2010220T3 (da)	2022-05-23
JP2009532467A (ja)	2009-09-10
PL2010220T3 (pl)	2022-08-16
PT2010220T (pt)	2022-05-20
AU2007240993A1 (en)	2007-11-01
EP2010220A2 (fr)	2009-01-07
US20110212914A1 (en)	2011-09-01
US20070243218A1 (en)	2007-10-18
PL2010220T4 (pl)	2022-08-16
AU2007240993B2 (en)	2013-08-01
WO2007123800A3 (fr)	2007-12-21
NZ571537A (en)	2012-06-29
EP2010220B1 (fr)	2022-02-16
JP5433881B2 (ja)	2014-03-05
WO2007123800A2 (fr)	2007-11-01
EP2010220A4 (fr)	2013-05-01
HUE058709T2 (hu)	2022-09-28

Legal Events

Date	Code	Title	Description
2012-01-11	EEER	Examination request
2014-10-05	FZDE	Discontinued	Effective date: 20140808

Publication	Publication Date	Title
AU2007240993B2 (en)	2013-08-01	Stabilized pentosan polysulfate (PPS) formulations and methods of analyzing them
Volpi	2007	Analytical aspects of pharmaceutical grade chondroitin sulfates
Barthe et al.	2004	In vitro intestinal degradation and absorption of chondroitin sulfate, a glycosaminoglycan drug
Václavíková et al.	2013	Isotachophoretic determination of glucosamine and chondroitin sulphate in dietary supplements.
DE60018061T2 (de)	2006-04-13	Verwendung von glykosaminoglykane zur behandlung seniler demenz
Volpi et al.	2021	Structural definition of terrestrial chondroitin sulfate of various origin and repeatability of the production process
TWI737229B (zh)	2021-08-21	製劑的製造方法、製劑製造的管理方法及製劑的檢查方法
TWI594757B (zh)	2017-08-11	製劑的製造方法、管理方法及檢查方法
Galeotti et al.	2014	Selective removal of keratan sulfate in chondroitin sulfate samples by sequential precipitation with ethanol
CN105136697A (zh)	2015-12-09	一种***磷酸钠注射液中间体检验方法
Kowalski et al.	1999	Determination of streptomycin in eggs yolk by capillary electrophoresis
Liu et al.	2011	Mass balance analysis of contaminated heparin product
Jaques et al.	1973	Variation in commercial heparin and its relation to the problem of heparin standardization for clinical use
EP2968400B1 (fr)	2019-05-08	Activateurs de résorption utilisés comme additifs pour améliorer la formulation orale d'héparines de faible poids moléculaire
Ruckmani et al.	2014	A new simple and rapid method for the determination of sodium hyaluronate in active pharmaceutical ingredient and ophthalmic formulations by DP5 photorode
Shen et al.	2009	Determination of benzalkonium chloride in viscous ophthalmic drops of azithromycin by high-performance liquid chromatography
DE1617659C3 (de)	1982-01-21	Interferonbildendes Arzneimittel und dessen Verwendung
Begg et al.	1966	Hyaluronic acid and protein in simple ganglia and Heberden's nodes.
Laurent et al.	1986	Fate of exogenous hyaluronic acid in the middle ear
JP6043922B2 (ja)	2016-12-14	抽出物及び該抽出物を含有する製剤
US20240102978A1 (en)	2024-03-28	Improved method for polysaccharide quantification
Behbood et al.	2017	Analytical and physicochemical characterization of cefquinome using capillary electrophoresis
CN114609128B (zh)	2024-06-14	测定蜗牛糖胺聚糖含量的方法及其用途
Holt et al.	1968	Mucopolysaccharides in synovial fluid. Effect of aspirin and indomethacin on hyaluronic acid.
KORKMAZ et al.	2020	QUALITY EVALUATION OF BIOSIMILAR MEDICINES: AN OVERVIEW